Q3 FY24 Earnings

Quarterly results for Indian listed companies · Oct–Dec 2023 · quarter ended 31 Dec 2023

Clear filters 201–222 of 222
CompanyRevenue (₹ Cr)Profit (₹ Cr)Per share8Q profit
Symbol Sector Reported YoY QoQ Reported YoY EPS vs consensus Trend
Dolphin Medical Services Ltd
Healthcare0n/aup+11.1%0n/a0.00No estimate
RUBRAMEDICAMENTSLTD Centuple Global Ltd
Healthcare0n/adown-41.4%0n/a0.11No estimate
ORTINGLOBE Ortin Global Ltd
Healthcare0n/adown-48.1%-3n/a-3.43No estimate
SHYAMAINFOLTD Shyama Computronics and Services Ltd
Healthcare0n/a0.0%0n/a0.00No estimate
GENOMICVALLEYBIOTECHLTD Genomic Valley Biotech Ltd
Healthcare0n/adown-42.9%0n/a0.07No estimate
CELESTIAL Celestial Biolabs Ltd
Healthcare0up+33.3%0.0%-0n/a-0.02No estimate
PHARMAIDSPHARMACEUTICALSLTD Pharmaids Pharmaceuticals Ltd
Healthcare0n/an/a-1n/a-0.54No estimate
TRANSCHEMLTD Transchem Ltd
Healthcare0n/an/a1n/a0.93No estimate
CHEMOPHARMALABORATORIESLTD Starsource Multitrade Ltd
Healthcare0n/an/a1n/a4.53No estimate
TRIOCHEMPRODUCTSLTD Triochem Products Ltd
Healthcare0n/an/a-0n/a-8.16No estimate
GENESISIBRCINDIALTD CCME Global Ltd
Healthcare0n/an/a-0n/a-0.02No estimate
KABRADRUGSLTD Kabra Drugs Ltd
Healthcare0n/an/a-0n/a-0.25No estimate
BACILPHARMALTD Bacil Pharma Ltd
Healthcare0n/an/a-0n/a-0.03No estimate
KAMRONLABORATORIESLTD Adline Chem Lab Ltd
Healthcare0n/an/a-0n/a-0.03No estimate
WELCUREDRUGSPHARMACEUTICALSLTD Welcure Drugs & Pharmaceuticals Ltd
Healthcare0n/an/a0n/a0.00No estimate
REKVINALABORATORIESLTD Rekvina Labs Ltd
Healthcare0n/an/a0n/a0.00No estimate
VENMAXDRUGSPHARMACEUTICALSLTD Venmax Drugs & Pharmaceuticals Ltd
Healthcare0n/an/a0n/a0.06No estimate
RAYMEDLABSLTD Cresanto Global Limited
Healthcare0n/an/a-0n/a-0.05No estimate
MPS Pharmaa Ltd
Healthcare0n/an/a-0n/a-0.11No estimate
TAKE Take Ltd
Healthcare0n/adown-100.0%-2n/a-0.14No estimate
Transchem Ltd
Healthcare0n/an/a1n/a0.93No estimate
Harleystreet Pharmaceuticals Ltd(merged)
Healthcaren/an/a127up+11.4%4.06No estimate

About Q3 FY24 earnings data

When are Q3 FY24 results announced?
Q3 FY24 covers the Oct–Dec 2023 quarter. Indian listed companies have up to 45 days after a quarter closes to file their results — 60 days for the January–March quarter — so results arrive in a wave over the weeks that follow rather than all at once. A quarter that has only just ended will look sparse and fill in.
Why do some Q3 FY24 growth figures show "n/a" instead of a percentage?
Growth is left blank whenever the comparison period was not profitable. A percentage change measured from a loss is arithmetic without meaning — a swing from a ₹10 crore loss to a ₹10 crore profit is not "200% growth", and publishing it as such would flatter the company. The reported figures for both periods are still shown, so the change is there to read directly.
Does the beat/miss verdict cover every company?
No analyst consensus was available for Q3 FY24, so no beat/miss verdict is shown. Revenue and profit growth are taken from reported results and cover every company in the table.
What counts as an in-line result rather than a beat or a miss?
Reported earnings per share within ±2% of the consensus estimate. The band is set there because a tighter one classifies rounding as news, and a wider one swallows surprises that genuinely moved a stock.
Are the figures consolidated or standalone?
Consolidated where a company reports on that basis, standalone otherwise, with all money in ₹ crore. Figures are as filed by the company with the exchanges (NSE/BSE); they are not restated or adjusted.
What does the 8-quarter trend line show?
Quarterly net profit for the last eight quarters, oldest on the left, always ending on the quarter shown in the row. Two years covers both the seasonal shape of the business and its direction. The line breaks where a quarter is missing rather than drawing across the gap, so a break is a real absence of data and not a reported collapse.
How do I find only the companies that beat estimates in Q3 FY24?
Use the Result filter above the table and choose Beat, or sort by EPS surprise to rank every covered company by how far it landed from consensus. Both are reflected in the page URL, so a filtered view can be bookmarked or shared.

Figures are as reported by companies in their quarterly filings to the exchanges (NSE/BSE), in ₹ crore. Consolidated results are shown where a company reports them, otherwise standalone. Year-on-year and quarter-on-quarter growth is omitted where the comparison period was loss-making, since a percentage change from a negative base is not meaningful. Analyst consensus is an estimate, not a forecast of outcome.